Operating Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Summary of segmental information
Revenues	$ 1,725,545	$ 990,971	$ 2,845,318	$ 2,321,855
Income/(Loss) from Operations	(1,589,290)	(2,316,829)	(3,983,391)	(4,055,019)
Amortization and Depreciation Expense	11,170	18,621	22,384	39,671
Interest Income, Net	32,948	5,231	49,843	9,984
Share-Based Compensation	90,425	94,047	198,395	240,674
Identifiable Assets	6,152,139		6,152,139		$ 9,549,651
Vaccines/BioDefense [Member]
Summary of segmental information
Revenues	1,449,044	990,971	2,258,300	2,321,855
Income/(Loss) from Operations	30,299	197,270	(55,906)	333,870
Amortization and Depreciation Expense	4,512	9,611	8,992	19,380
Share-Based Compensation	12,818	14,973	28,486	32,971
Identifiable Assets	1,443,142		1,443,142		906,416
BioTherapeutics [Member]
Summary of segmental information
Revenues	276,501		587,018
Income/(Loss) from Operations	(923,960)	(1,574,261)	(2,445,308)	(2,601,816)
Amortization and Depreciation Expense	5,345	8,077	10,729	17,644
Share-Based Compensation	21,898	22,827	50,216	72,597
Identifiable Assets	166,364		166,364		116,344
Corporate [Member]
Summary of segmental information
Income/(Loss) from Operations	(695,629)	(939,838)	(1,482,177)	(1,787,073)
Amortization and Depreciation Expense	1,313	933	2,663	2,647
Interest Income, Net	32,948	5,231	49,843	9,984
Share-Based Compensation	55,709	$ 56,247	119,693	$ 135,106
Identifiable Assets	$ 4,542,632		$ 4,542,632		$ 8,526,891